Sponsor Dossier
Bristol-Myers Squibb
Sponsor Dossier for Bristol-Myers Squibb. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: APIXABAN-APX
- Brand: AUGTYRO
- Brand: CAMZYOS
- Brand: ELIQUIS
- Brand: EMPLICITI
- Brand: EVOTAZ
- Brand: INREBIC
- Brand: Istodax
About
Bristol-Myers Squibb is an Australian Private Company with ABN 33004333322, registered in Victoria. The company is active and registered for GST.
Portfolio
Bristol-Myers Squibb has 24 brands on the ARTG, of which 22 are indexable. The portfolio includes 21 brands with Product Information on file, 14 brands with at least one PBS-listed item, 17 brands with PBAC outcomes on record, and 17 brands with AusPARs on record.
Therapeutic focus
— Oncology: 15 brands — Haematology: 3 brands — Neurology: 2 brands — Dermatology: 1 brand — Cardiology: 1 brand — Immunology: 1 brand — Infectious Disease: 1 brand
PBS footprint
Fourteen brands in the Bristol-Myers Squibb portfolio are PBS-listed, with the portfolio touching the PBS schedule most recently on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Bristol-Myers Squibb was on 1 November 2025, with 17 brands holding PBAC outcomes on record. The latest AusPAR was issued on 23 July 2025, with 17 brands holding AusPARs on record.